Evaluation of prognostic value of cyclin D1, cyclin E, p27 protein and proliferative activity PCNA in ovarian carcinomas;Ocena wartości prognostycznej cykliny D1, cykliny E, białka p27 i aktywności proliferacyjnej PCNA w rakach jajnika

Onkologia Polska

Volumn 10, Issue 3, 2007, Pages 97-104

  Sobańska, Ewa ^a   Bar, Julia K ^a   Gryboś, Marian ^a   Gabryś, Marian ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Cyclin D1; Cyclin E; Ovarian carcinoma; p27 protein; PCNA

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; CYCLIN E; CYCLINE; MONOCLONAL ANTIBODY; PROTEIN P27; REGULATOR PROTEIN;

ADVANCED CANCER; ARTICLE; ASCITES FLUID; BENIGN TUMOR; CANCER GRADING; CANCER STAGING; CELL CYCLE REGULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYST FLUID; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; OVARY TUMOR; OVERALL SURVIVAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; TISSUE SECTION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; UNDIFFERENTIATED CARCINOMA; UNIVARIATE ANALYSIS;

EID: 38149026135     PISSN: 15056732     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Cordon-Cardo C.: Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am. J. Pathol. 1995, 147, 545-560.
2. Barbieri F., Cagnoli M., Ragni N. i wsp.: Expression of cyclin D1 correlates with malignancy in human ovarian tumours. Br. J. Cancer 1997, 75, 1263-1268.
3. Worsley S.D., Ponder B.A., Davies B.R.: Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol. Oncol. 1997, 64, 189-195.
4. Dhar K.K., Branigan K., Parkes J. i wsp.: Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells. Br. J. Cancer 1999, 81, 1174-1181.
5. Rosenberg E., Demopoulos R.I., Zeleniuch-Jacquotte A. i wsp.: Expression of cell cycle regulators p57 (KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Hum. Pathol. 2001, 32, 808-813.
6. Milde-Langosch K., Hagen M., Bamberger A.M., Loning T.: Expression and prognostic value of cell-cycle regulatory proteins, Rb, p 16MTS1, p21WAF1, p27KIP1, cyclin E and cyclin D2 in ovarian cancer. Int. J. Gynecol. Pathol. 2003, 22, 168-174.
7. Catzavelos G.C., Bhaattacharya N., Ung Y.C. i wsp.: Decreased levels of the cell-cycle inhibitor p27kip1 protein: prognostic implications in primary breast cancer. Nat. Med. 1997, 3, 227-230.
8. Loda M., Cukor B., Tam S.W. i wsp.: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 1997, 3, 231-234.
9. Pagano M., Tam S.W., Theodoras A.M. i wsp.: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269, 682-685.
10. Mori M., Mimori K., Shiraishi T. i wsp.: p27 expression and gastric carcinoma. Nat. Med. 1997, 3, 593-598.
11. Sui L., Tokuda M., Ohno M. i wsp.: The concurrent expression of p27kip1 and cyclin D1 in epithelial ovarian tumors. Gynecol. Oncol. 1999, 73, 202-209.
12. Sui L., Dong Y., Ohno M. i wsp.: Implication of malignancy and prognosis of p27 (kip1), cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol. Oncol. 2001, 83, 56-63.
13. Fredersdorf S., Burns J., Milne A.M. i wsp.: High level expression of p27kip1 and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27kip1 and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA 1997, 94, 6380-6385.
14. Bali A., O'Brien P.M., Edwards L.S. i wsp.: Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin. Cancer Res. 2004, 10, 5168-5177.
15. Drobnjak M., Osman I., Scher H.I. i wsp.: Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin. Cancer Res. 2000, 6, 1891-1895
16. Senderowicz A.M.: The cell cycle as a target for cancer therapy. Basic and clinical findings with the small molecule inhibitors Flavopiridol and UCN-01. Oncologist 2002, 7, supl. 3, 12-19.
17. Raju U., Nakata E., Mason K.A. i wsp.: Flavopiddol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res. 2003, 63, 3263-3267.
18. Bedrosian L, Lu K.H., Verschraegen C., Keyomarsi K.: Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 2004, 23, 2648-2657.
19. Itamochi H., Kigawa J., Akeshima R. i wsp.: Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology 2002, 62, 349-353.
20. Smith M.L., Seo Y.R.: Sensitivity ofcyclin E-overexpressing cells to cisplatin/taxol combinations. Anticancer Res. 2000, 20, 2537-2539.
21. Masciullo V., Ferrandina G., Pucci B. i wsp.: p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clin. Cancer Res. 2000, 6, 4816-4822.
22. Davidson B., Risberg B., Berner A. i wsp.: Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions - biological and prognostic implications. Gynecol. Oncol. 2001, 83, 249-256.
23. Saegusa M., Machida D., Okayasu I.: Possible associations among expression of p14ARF, p21WAF1/CIP1, p27KIP1, and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas. Cancer 2001, 92,1177-1189.
24. Hurteau J.A., Allison B.M., Brutkiewicz S.A. i wsp.: Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27Kip1 in epithelial ovarian cancer. Gynecol. Oncol. 2001, 83, 292-298.
25. Psyrri A., Bamias A., Yu Z. i wsp.: Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survivalin epithelial ovarian cancer. Clin. Cancer Res. 2005, 11, 8384--8390.
26. Rosen D.G., Yang G., Cai K.Q. i wsp.: Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin. Cancer Res. 2005, 11, 632-637.
27. Xing H., Wang S., Hu K. i wsp.: Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy. J. Cancer Res. Clin. Oncol. 2005, 131, 511-519.
28. Nahta R., Takahashi T., Ueno N.T., Esteva F.J.: P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004, 64, 3981-3986.
29. Bookman M.A.: Biological therapy of ovarian cancer: Current directions. Semin. Oncol. 1998, 25, 381-396.